A release date for Banjo-Kazooie on Nintendo Switch Online has been revealed, and it's coming sooner than you think.

In today’s fast-paced market, there isn't a one-size-fits-all approach to helping a buyer compete in an all-cash world. However, there are various tactics and strategies that can certainly help. Here are a few.

Rare’s classic N64 platformer Banjo-Kazooie is coming to the Nintendo Switch Online + Expansion Pack game library tomorrow, 20th January. The game will be playable via emulation for all members of the more expensive subscription. Embark on a wild quest with an unlikely pair! The adventures of Banjo and Kazooie begin here! Banjo-Kazooie is coming to #NintendoSwitch for #NintendoSwitchOnline + Expansion Pack members on 1/20! #Nintendo64 pic.twitter.com/R349r8gbvD — Nintendo of America (@NintendoAmerica) January 19, 2022 Banjo-Kazooie was a 3D platforming icon that emerged in the wake of Super Mario 64 revolutionised the genre. The game stars Banjo the bear and his truty feathered companion Kazooie as they set off on an adventure to rescue Banjo’s sister Tooty who has been kidnapped by Gruntilda the witch. Adding Banjo-Kazooie is an example of Nintendo managing to navigate the tricky waters of game licensing. While the game was released when Rare was owned by Nintendo in the 1990s, the studio was acquired by Microsoft in the early 2000s and the IP that they had created (such as Banjo-Kazooie and Perfect Dark) went with them. For the bird and bear to return to Switch, Microsoft will have licensed the game to Nintendo. Some have speculated that needing to cut licensing deals is part of the reason why the Expansion Pack is a paid add-on to Switch Online. Further Reading: Is Nintendo Switch Online + Expansion Pack’s N64 emulation good enough? It’s another fan-pleasing addition to Expansion Pack, but continues to demonstrate that Nintendo are content to release games at a slow pace. Nintendo Switch Online – Expansion Pack launched at the end of October, featuring a higher price point than the regular Switch Online subscription but promising a growing library of N64 and Sega Mega Drive games. The initial offering included nine N64 titles, with games like Super Mario 64, Ocarina of Time, Lylat Wars and more included. This was then expanded to include Paper Mario in December. However, as soon as Expansion Pack launched, users complained about the quality of the game emulation that Nintendo was providing, with graphical deficiencies compared to previous efforts that weren’t always consistent or authentic to the original games. Nintendo has yet to address these complaints, though it’s doubtful that they’ll make a big song and dance about it, because that would mean admitting anything was wrong in the first place. Future additions to Nintendo Switch Online have already been confirmed, though it’s just a case of waiting to find out when games like F-Zero X, Kirby 64, Majora’s Mask and Pokémon Snap are added.

As the NFT craze continues to sweep across the industries of the world, it’s clear that the technology is moving away from the fringe “tech enthusiast” space and into the limelight. At this point, it is safe to assume that everyone has heard of cryptocurrencies such as Bitcoin and Ethereum, but crypto alone is far from the only game in town. NFTs (non-fungible tokens) are quickly surpassing cryptocurrencies in popularity as they gain mainstream attention for their use in sports, gaming, contemporary art, and even real estate. Currently, the NFT market boasts a multi-billion dollar valuation which is bigger than many well-established cryptocurrencies projects that have been around for several years. The market is projected to grow even more as companies and organizations begin to adopt these NFTs across an array of different industries. However, while they are mostly associated with art or gaming and collectibles NFTs are also making waves in the sports industry. NFTs in Sports The world of sports makes for a prime example of how NFTs can truly change the way fans interact with each other as well as with their favorite teams. Consider, for example, fans of a specific football club. Every year season ticket holders have to decide whether or not they’ll renew their tickets as prices increase. In addition to this, members must also decide if they want to upgrade their seats or even purchase new ones. Every year, the cost of renewing your tickets increases, which means that fans must either fork out more money or risk losing their seats to someone else. As a result, many fans are forced to make the difficult decision between spending money on football tickets or other day-to-day necessities like groceries and utilities. However, NFTs can eliminate this issue as they can be used by the sports team to galvanize funds from fans while allowing fans holding season tickets to earn a percentage of the revenue the team receives. In essence, the fans can earn tokens by holding their NFTs and spend those proprietary tokens by engaging in various activities and experiences with their favorite club. With NFTs, the fans no longer have to choose between renewing their tickets or paying for other necessities because they can do both simultaneously. For instance, after attending a match, fans will collect tokens which they can then spend on other experiences like meeting their favorite players, watching training sessions, or even taking a tour of the stadium. This gives the fan a chance to be truly invested in the team’s success and also helps to keep the most devoted fans coming back year after year because they have access to exclusive team events and experiences which are only available to the team’s NFT holders. Not only do NFTs allow teams to attract more season ticket holders by giving them exclusive access to club-related experiences, but they also allow clubs to reduce ticket prices. In addition, this allows teams to earn money from NFTs as fans buy them and redeem them at games or events where the team can take a percentage of each purchase. MetaFans NFTs The utility of NFTs in the world of sports goes beyond the memorabilia of digital art or other forms of collectibles. However, existing sports NFT projects primarily focus on selling NFTs in mass instead of offering the most value to NFTs holders and creators. MetaFans seeks to offer a unique solution with a sports NFT platform that combines the love for collecting sports memorabilia with various levels of utility to encourage the development of a sports fandom. MetaFans is the first-of-its-kind company to offer a collection of sports NFTs that go beyond cookie-cutter digital art that currently proliferates the sports NFT marketplace to offer a new era of collectibles with real-world value and experiences. Created by cofounders Maxfield Bala and Marion Phillips MetaFans uses NFTs to foster a community of fans who can gain residual reward opportunities as well as have real-life experiences with their favorite teams. With the initial launch of its first 10,000 Sports Fan NFTs, not to mention a reward-driven NFT collection called FanEpack NFTs, MetaFans is set to go beyond the world of sports with a strategy that not only benefits NFT collectors but also supports respectable brands, athletes, musicians, gamers, and actors to mention a few. MetaFans Diamond Club Collection MetaFans’ Diamond Club Collection is the main attraction the company offers NFT collectors and enthusiasts. It contains a set of 10,000 unique digital collectibles built on Ethereum’s ERC-721 standard. From this collection, there are over 700 unique traits across 4 avatars that are designed by Maxfield Bala who spent hours illustrating each trait by hand. Bala is an internationally renowned illustrator and fine artist who has worked with brands such as Disney, the NFL, Coca-Cola, and Samsung. He has collaborated on various mainstream artistic projects around the world. Each NFT in the Diamond Club (DC) Collection gives holders membership to an exclusive group of successful blue-chip investors, entrepreneurs, and lifestyle curators within the MetaFans ecosystem. This is the MetaFans approach at enabling fans to have access to a digital country club for sports fans. With this feature, NFT holders in the MetaFans platforms will be able to join an eccentric ever-growing community of fans while still enjoying the multiple benefits and utilities of owning those NFTs. Benefits of Owning MetaFans NFTs Apart from the perks that come with owning a MetaFans DC NFT, the opportunity to mind additional NFTs within the MetaFans platform also comes with additional features. For instance, MetaFans offers the Owners Box Guest NFTs, which grant holders the privilege and power of having the best seats in the house during sports and entertainment events. This set of NFTs includes super rare collectibles completely hand-drawn by Bala (the project’s founding artist). Also, those who hold Genesis MetaFans NFTs in the DC collection will be able to mint a FREE MetaFans FanEpack NFT that can be redeemed for various giveaways and benefits separate from the main MetaFans DC NFTs. Some of the benefits include a claim to real-world merchandise, NFTs of clothing and accessories that can be used with various avatars in the metaverse, and access to future trade-up programs such as collecting enough FanEpack NFTs to burn for a Backpack. Conclusion: MetaFans Future Collaborations Sporting teams around the globe are quickly realizing that NFTs are the future, especially for sports fans. They allow fans to truly interact with their favorite clubs in a way previously thought impossible. While many teams have recognized this potential, they have yet to fully capitalize on it because they don’t understand the industry well enough. MetaFans was created to fill this hole, which is the company’s core mission. Once a fan owns a MetaFans NFT, they can use it as a ticket replacement for any future event held by their favorite teams and clubs throughout the country or around the world. These collectibles can also be used as promotional items during special events, giveaways, and other activities within the team’s community. As for athletes, many are already part of the MetaFans ecosystem, given MetaFans plans to collaborate with professional athletes, music stars, and gaming influencers. NFT holders in the MetaFans community will have advanced access to NFT collections launched by various sports stars, musicians, and influencers at a discounted price. These and other developments in the MetaFans ecosystem will go a long way to give amazing rewards and gifts to NFT holders in the world of sports and entertainment.

TOKYO, Jan 19, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has enrolled the first subject in the phase II/III study (Tau NexGen study). The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).

People who have genetic mutations of DIAD are known to develop Alzheimer's disease (AD) and will likely develop symptoms at around the same age their affected parents did, often in their 50s, 40s or even 30s. The major AD pathologies are amyloid plaque that consists of amyloid beta (Abeta) aggregates; neurofibrillary tangles; and intraneuronal aggregates of tau, all of which are believed to spread throughout the brain.

The purpose of the Tau NexGen study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational therapies in pre-symptomatic or symptomatic participants who have an AD-causing gene mutation. In March 2021, the DIAN-TU selected E2814, which was created from a research collaboration between Eisai and University College London, as the first investigational medicine among anti-tau drugs for the Tau NexGen study. With increasing evidence from clinical studies showing that targeting amyloid can reduce biomarkers of AD, the Tau NexGen clinical trial leaders selected Eisai's investigational anti-Abeta protofibril antibody lecanemab (BAN2401) as the background anti-amyloid therapy, and the study design was amended in November 2021.

Eisai positions neurology as a key therapeutic area, and it will continue to create innovation in the development of novel medicines based on cutting-edge neurology research as it seeks to contribute further to improving the benefits of affected individuals and their families in diseases with high unmet needs, such as dementia including AD.

About Dominantly Inherited Alzheimer Network (DIAN)

The DIAN is an international research effort focused on dominantly inherited Alzheimer's disease. Dominantly Inherited Alzheimer's disease (DIAD) is a rare form of Alzheimer's disease (AD) that causes memory loss and dementia in individuals -- typically while they are in their 30s to 50s. The disease affects less than 1% of the total population of people with AD. The aim of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) is to find solutions to treat or prevent this disease and, potentially, all forms of Alzheimer's. The DIAN-TU is an international public-private partnership dedicated to designing and managing interventional therapeutic trials for individuals with and at risk of DIAD.

About Tau NexGen study

The purpose of the Tau NexGen study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational therapies in people who have an AD-causing gene mutation. In the Tau NexGen study, symptomatic participants will be administered anti-amyloid beta (Abeta) protofibril antibody lecanemab for six months before being randomly assigned to also receive the anti-tau drug or a placebo. Since amyloid plaques accumulate before tau tangles in AD, this study design allows the researchers to assess whether amyloid removal clears the way for the anti-tau drug to function most effectively. Pre-symptomatic participants will be randomly assigned to receive the anti-tau drug or a placebo for a year before beginning lecanemab administration. By staggering the drugs in this way, the researchers will be able to evaluate the effects of the anti-tau drug alone before assessing the effects of the two drugs together. If the primary and secondary endpoints are positive in the analysis two years after the start of study, the study will be extended for another two years to assess whether the drug slows cognitive decline and has further effects on tau pathology.

About E2814

An investigational anti-microtubule binding region (MTBR) tau antibody, E2814 is being developed as a disease modifying agent for tauopathies including sporadic AD. Phase I clinical studies are underway. E2814 was discovered as part of the research collaboration between Eisai and University College London. E2814 is designed to prevent the spreading of tau seeds within the brains of affected individuals.

About Lecanemab (BAN2401)

Lecanemab is an investigational humanized monoclonal antibody for AD that is the result of a strategic research alliance between Eisai and BioArctic. Lecanemab selectively binds to neutralize and eliminate soluble, toxic Abeta aggregates (protofibrils) that are thought to contribute to the neurodegenerative process.

in AD. As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease. With regard to the results from pre-specified analysis at 18 months of treatment, Study 201 demonstrated reduction of brain Abeta accumulation (P<0.0001) and slowing of disease progression measured by ADCOMS* (P<0.05) in early AD subjects. The study did not achieve its primary outcome measure** at 12 months of treatment. The Study 201 open-label extension was initiated after completion of the Core period and a Gap period off treatment (average of 24 months) to evaluate safety and efficacy, and is underway.

Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement concluded with BioArctic in December 2007. In March 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab and the parties amended that agreement in October 2017. Currently, lecanemab is being studied in a pivotal Phase III clinical study in symptomatic early AD (Clarity AD), following the outcome of the Phase II clinical study ( Study 201). In July 2020 the Phase III clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, was initiated. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S., funded by the National Institute on Aging, part of the National Institutes of Health, and Eisai.

In September 2021, a rolling submission to the FDA of a Biologics License Application (BLA) for the treatment of early AD under the accelerated approval pathway was initiated. Lecanemab was granted Breakthrough Therapy designation in June 2021, a U.S. Food and Drug Administration (FDA) program intended to expedite the development and review of medicines for serious or life-threatening conditions.

* Developed by Eisai, ADCOMS (AD Composite Score) combines items from the ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale), CDR (Clinical Dementia Rating) and the MMSE (Mini- Mental State Examination) scales to enable a sensitive detection of changes in clinical functions of early AD symptoms and changes in memory.
** An 80% or higher estimated probability of demonstrating 25% or greater slowing in clinical decline at 12 months treatment measured by ADCOMS from baseline compared to placebo

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120

Eisai Inc (U.S.) Libby Holman 201-753-1945
Libby_Holman@eisai.com

Investor Contact:
Eisai Co., Ltd.
Investor Relations Department
TEL: +81-(0)70-8688-9685


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comE isai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has enrolled the first subject in the phase II/III study (Tau NexGen study).

Roblox Pet Fighting is a new Roblox game that wants to tap into the monster battling RPG craze started by Pokémon and many other games....

The post Roblox Pet Fighting Codes (January 2022) appeared first on ISK Mogul Adventures. Written by .

Nintendo has revealed that the N64 classic Banjo-Kazooie will be available to all Nintendo Switch Online + Expansion Pack members on January 20, 2022.

Rare’s jolly 3D platformer returns on January 20 Ever since Nintendo teased that Banjo-Kazooie was coming to Nintendo Switch in...

The post N64 classic Banjo-Kazooie joins Nintendo Switch Online this week appeared first on Destructoid.

NFTs are fast becoming an ubiquitous part of the digital economy. Once largely a digital art medium, NFTs are starting to encompass other art...

This article helps founders understand the different stages of funding

Home insurance isn’t the sexiest topic, but in the world of financial independence, predictability is quite an attractive trait to have. That’s why money nerds across the world value insurance […]

A court has ruled that Lake County failed to properly analyze how a Guenoc Valley development would affect evacuation routes in times of wildfire.